| On Line Home Study Programs |
|
The Clinical Imperative for Tight Glycemic Control
Program Overview
Tight glycemic control is the practice of using intravenous insulin in hyperglycemic patients to bring blood glucose levels back to normal. Research has shown that tight glycemic control dramatically improves clinical outcomes. Published data also show that it can offer significant savings to hospitals because of decreased morbidity and mortality.
Presentation
The program can be completed by viewing the PowerPoint® slide show (using Microsoft® PowerPoint® 97 or later), answering the post-test questions and completing the program evaluation on line. Statements of credit can be printed after successful completion of the program.
Program Information
- Target Audience
This continuing education program is beneficial for pharmacists in acute care settings who manage medication therapy for patients who require tight glycemic control.
This program is not accredited for Pharmacy Technicians.
- Learning Objectives
After participating in this program, the pharmacist should be able to:
- Differentiate between unrecognized diabetes and stress-related hyperglycemia
- Relate the importance of the prevalence of hyperglycemia in hospitalized patients to the need for tight glycemic control
- Summarize the possible reasons why tight glycemic control helps decrease mortality
- Cite the reason behind the protective effect of tight glycemic control, as suggested in the Van den Berghe study
- Compare and contrast pharmacoeconomic analyses as they relate to tight glycemic control
- Summarize the components of an effective implementation of a tight glycemic control protocol
Program Faculty
- Faculty Disclosure Statement
In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, Northeastern University Bouvé College of Health Sciences School of Pharmacy requires that faculty members disclose any relationship (e.g., shareholder, recipient of research grant, consultant, or member of an advisory committee) that the faculty may have with commercial companies whose products or services may be mentioned in their presentations. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on faculty presentations.
- Faculty and Disclosure Information
Daniel Hilleman, PharmD
Professor of Pharmacy Practice, Creighton University, School of Pharmacy and Allied Health Professions
Creighton University Medical Center
Omaha, Nebraska
- Speaker with Honoraria: Wyeth, Pfizer, Novartis, Abbott, Scios, Lifescan
- Does not plan on discussing unlabeled/investigational uses of a commercial product.
M. James Lenhard, MD, FACE, FACP
Diabetes and Metabolic Diseases Center
Wilmington, DE
Christiana Care Research Institute Diabetes and Metabolic Research Center
Newark, DE
- Speaker with Honorarium: Lifescan
- Does not plan on discussing unlabeled/investigational uses of a commercial product.
Bernadine C. Henderson, MS, FNP-C, CDE
Diabetes Disease Management Care Manager
Christiana Care Health System
Wilmington, Delaware
- Speaker with Honorarium: Aventis
- Does not plan on discussing unlabeled/investigational uses of a commercial product.
Program Support
Supported by an educational grant from LifeScan, Inc.
There is no fee for this program.
Continuing Education Accreditation Information
Northeastern University Bouvé College of Health Sciences School of Pharmacy is approved by the Accreditation Council on Pharmacy Education as a provider of continuing pharmacy education. Pharmacists successfully participating in this program will receive a statement of credit for one and one-half contact hours (0.15 CEU). Statements of Credit may be printed on-line after successful completion of the learning assessment (70%).
ACPE #027-000-05-030-H01. Initial release date July 1, 2005, Expires July 1, 2008.
Further Disclosure of Unlabeled Use and Disclaimer
|
